Viva Valeant

Valeant Pharmaceuticals reported Q3 results exceeding estimates, with profit at $2.74 a share and revenue rising 36 percent, to $2.8 billion, as sales for dermatology and contact lens products climbed. The company said it may sell or spinoff its portfolio of neurological drugs.